ArticleBioinformatics (Oxford, England)2026
MOZAIC: compound growth via in silico reactions and global optimization using Conformational Space Annealing.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
motivationFragment-based drug discovery (FBDD) efficiently explores chemical space by combining small molecular fragments. Advances in computational methods are accelerating the development of algorithm- and AI-based approaches in FBDD. However, it should be noted that certain methods do not provide synthetic pathways to obtain the proposed compounds. Consequently, these molecules might not be synthesized easily.
resultsWe present MOZAIC, a reaction-based fragment-growing framework that combines in silico reactions with Conformational Space Annealing for global molecular optimization. MOZAIC generates compounds through SMARTS-defined organic reactions, preserving reaction histories and providing putative synthetic routes. Across benchmark targets, MOZAIC produced chemically diverse molecules with balanced improvements in predicted binding affinity, drug-likeness, and synthetic accessibility. Compared with existing fragment-growing and generative approaches, MOZAIC achieved broad scaffold coverage while maintaining target-directed optimization. Its modular objective function also enabled alternative design goals, such as improving predicted solubility while maintaining binding affinity. AVAILABILITY AND IMPLEMENTATION: MOZAIC is available at https://github.com/kucm-lsbi/MOZAIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.